×
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
×
What are you looking for?
Search for:
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
Interview Series | In Pursuit of A Cancer Cure: Conversations with Immunotherapy Advocates – Dr Ramy Ibrahim, CMO at PICI
by
tessathe
on
January 9, 2020
in
news-videos
<< Back to Press Releases & Events
Previous Reading
Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020
Next Reading
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma